Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
Active, not recruiting · NCT06056895 · Registry updated 2026-08-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma | DNA Virus Infections, Infections, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Tumor Virus Infections, adenocarcinoma, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, viral infectious disease | Active, not recruiting | Phase 2 | 2026-08-06 | NCT06056895 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Incyte Corporation | 153 |
| University of Washington | 397 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | United States | 140 |